Vemurafenib and ipilimumab: A promising combination? Results of a case series (Q36821040)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Vemurafenib and ipilimumab: A promising combination? Results of a case series (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

0 references

Antonia Dimitrakopoulou-Strauss

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Jessica C Hassel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Sophia B Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Frank Meiss

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Friedegund Meier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Dirk Jäger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Alexander H Enk

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

29 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

e1101207

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

3 April 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Improved overall survival in melanoma with combined dabrafenib and trametinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Hepatotoxicity with combination of vemurafenib and ipilimumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839308

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F2162402X.2015.1101207

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F2162402X.2015.1101207

10.1080/2162402X.2015.1101207

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27141385%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

27141385

1 reference